Innocan Pharma Corporation · CSE:INNO
Innocan Pharma — Investor Presentation (February 2023)
28 slides from Innocan Pharma's investor presentation, February 2023
Slide 1: Cannabinoids Drug Delivery
Cannabinoids Drug Delivery Making the CBD Revolution a Reality Investor Presentation, February 2023 CSE: INNO | OTC: INNPF | FSE: IP4
Slide 2: Disclosure
Disclosure Contents of this presentation of Innocan Pharma Corporation (“Innocan Pharma”, the “Company”, “we”, “us” or “our”) are provided for general information purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction. This presentati
Slide 3: Enhancing the Efficacy of Cannabinoids
LPT CBD Enhancing the CBD loaded liposome platform facilitating exact dosing, prolonged and controlled release of CBD Efficacy of into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. Cannabinoids CLX CBD Innoca
Slide 4: Management Team
Management Team IRIS BINCOVICH NELSON HALPERN, FCPA, FCA, TEP Chief Executive Officer Chief Financial Officer Iris Bincovich is the CEO of Innocan Pharma ($INNO $INNPF $IP4). Extensive experience with public and private companies. Member of Iris's background is in the healthcare and biotech industri
Slide 5: Advisory Committee
Advisory Committee RICHARD SERBIN IZHAR SHAY Scientific Advisor Advisor Richard Serbin is a regulation attorney, a patent attorney, and a pharmacist. Dr. Mitchell Kline is a board-certified, fellowship-trained surgical and clinical dermatologist, He has worked in the pharmaceutical industry for over
Slide 6: Special Advisors
Special Advisors Prof. Chezy Barenholz Antonio Benitz - Animal Health R&D Advisor Head of the Laboratory of Membrane and Antonio has a proven track record for bringing Liposome Research at the Hebrew University, pharmaceutical products through registration Jerusalem, Israel. 46 years experience in t
Slide 7: Innocan Pharma
Innocan Pharma Founded in 2017 by leading Made major achievements Building the groundwork pharma companies' ex- in administering CBD commercialization in veterinary executives through Liposome field as part of the expansion to the human field in the future LPT R&D led by Prof. Chezy Premium Innocan
Slide 8: Innocan Pharma Intellectual Property
The IP scope of the three disciplines can be elaborated as follows: Liposomes Cannabinoids Innocan Pharma The IP portfolio in this category is established as part of a corporation with Yissum (The Hebrew University applied science). Two patent Intellectual Property families in this category are in a
Slide 9: Innocan's Roadmap
Innocan’s Roadmap Pre-IND (FDA Meeting), Veterinary Exploring Commercialization in 2023 Pharma IP – Liposome Technology Entering Safety, Toxicity & Human FDA Preliminary Procedures Innocan's Science Accelerating Commercialization IP White-Labeling of IP in 2023 Non-Pharma IP Derma & Pain Relief E-co
Slide 10: Innocan's Potential Landscape
Innocan’s Potential Landscape Veterinary USD 29.4 billion 74.3% of dog owners 24% of pet owners is the global veterinary reported being comfortable – Dogs medicine estimated talking to vets about CBD consume CBD-based products market size in 2021 treatments USD 3.6 billion Big Pharma Liposomal suspe
Slide 11: The Challenge, The Medical Potential, The Commercial Potential
The Challenge The Medical Potential The Commercial Potential CBD suffers robust degradation in It has been shown by many Both Veterinary and Human the liver after being consumed researches that CBD has inherent treatment paths hold the potential to traditionally, making it a anti-inflammatory, pain
Slide 12: The Challenge: CBD Low Bioavailability
The Challenge: CBD Low Bioavailability Current CBD administration platforms have a low bioavailability of between 6-35%* • Cannabidiol is utilized as a therapeutic treatment for multiple conditions due to its potential for health and healing. • Its high safety profile makes it an appealing alternati
Slide 13: Innocan Solution: LPT – Injectable Cannabinoids Delivery Platform
Innocan Solution: Hydrogel LPT – Injectable CBD Cannabinoids Delivery Platform A unique CBD-loaded Liposome Platform Technology (LPT) facilitating exact dosing, prolonged and CBD-Loaded controlled release of CBD into the Liposome bloodstream Liposomes are spherical vehicles composed of a few layers
Slide 14: CBD-Loaded Liposome Platform Technology (LPT): Bioavailability Results
CBD-Loaded Liposome Platform Technology (LPT): Bioavailability Results ~100% CBD Bioavailability in a Dog Clinical Study Platform Inhalation Sources: Daily CBD; Yahoo Finance | 14
Slide 15: CBD-Loaded Liposome Platform Technology (LPT): Bioavailability Results
CBD-Loaded Liposome Platform Technology (LPT): Bioavailability Results • Ensure the prolonged & controlled release of CBD into the bloodstream for at least 42 days after one injection • High loading of CBD in the liposome - 1 injection lasts for over 4 weeks = Orally 2 times a 1 LPT local day for 42
Slide 16: LPT: Injectable CBD Delivery Platform
LPT: Injectable CBD Delivery Platform Achieving significant CBD level in dogs' plasma with the LPT, is a big step towards the drug's clinical studies in humans. The LPT in dog study results open the door to a wide range of therapeutic possibilities. • Drug performance in dogs is very similar to huma
Slide 17: Clinical Success: Veterinary Epilepsy
Clinical Success: Veterinary Epilepsy • Positive results in a preclinical trial involving a dog with refractory (drug-resistant) epilepsy. • The results demonstrated that the frequency and the intensity of the dog's epileptic seizures decreased significantly. • Since the last LPT injection on April
Slide 18: Clinical Success: Veterinary Pain Management
Clinical Success: Veterinary Pain Management • Successful preclinical trials in dogs with osteoarthritis. • A case entailing the clinical condition of Goody, an 8-year-old male mixed-breed dog, who suffers from severe osteoarthritis in most of his joints, and severe muscle atrophy, mostly surroundin
Slide 19: Clinical Success: Dermal Cosmetics
Clinical Success: Innocan Pharma’s in-house R&D team develops products integrating the most advanced technology and Dermal Cosmetics a wide range of ingredients to ensure that the products exceed performance expectations. The products are trademarked and distributed in Canada, France, UK, Germany, P
Slide 20: Clinical Success: Innovative Topicals
Clinical Success: Innovative Topicals The studies were conducted by an independent research laboratory: INOVAPOTEK, Pharmaceutical Research and Development in Portugal Anti-Wrinkles Efficacy Study Anti-Puffiness Efficacy Anti-Wrinkles Efficacy Study for Sleeping Mask Study for Eye Serum for Facial S
Slide 21: Innocan's Pharma Breakthroughs
Innocan's Pharma Breakthroughs Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary Innocan Pharma Reports Another Successful Result from LPT CBD Liposomal Delivery Platform a Pre-Clinical Study on a Dog Suffering from Refractory August 11, 2022 (D
Slide 22: Innocan in the News
Innocan in the News Professor Chezy Barenholz On A Case Report of a CBD-Powered Revolution in Subcutaneously Injected Pharmaceuticals Don’t Wait for US Legalization, Liposomal Cannabidiol InnoCan Pharma Reports Here Are 4 Cannabis Stocks to Formulation Used as a July 12, 2022 Impressive Preclinical
Slide 23: Capitalization
Capitalization CSE: INNO | OTC: INNPF | FSE: IP4 Share Price(1) $0.30 Basic Shares Outstanding(2) 249.6 In-The-Money Options(2)(3) 11.9 In-The-Money Warrants(2)(3) 0.4 F.D. Shares Outstanding 261.9 F.D. Market Capitalization $78.6 Cash(2) $8.7 Cash from In-The-Money Dilutive $2.2 Securities(2)(3) De
Slide 24: Innocan Fund Raising: Financial
September 2019 IPO $1.2M March 2020 Secondary $4.7M October 2021 PIP $6M April 2019 PIP $4M August 2018 Crowd Funding of $1.2M Innocan Fund Raising: Financial Within two years, Innocan Pharma has accelerated the expiry date of issued warrants three times as a result of achieving certain milestones.
Slide 25: Comparable: Value Driver Potential in the Veterinary Space
Comparable: Value Driver Potential* in the Veterinary Space June 2022 Boehringer Ingelheim, a global leader in animal health, and CarthroniX, a biopharmaceutical company focused on developing small molecule- based therapies for degenerative and aging-related diseases, announce that they have entered
Slide 26: Comparable: Value Driver Potential
Comparable: Value Driver Potential* December 2021 Pharmaceutical giant Pfizer Inc. is entering the cannabis space via the $6.7 billion acquisition of Arena Pharmaceuticals, Inc. The two publicly- traded companies confirmed that they have signed a definitive agreement under which Pfizer will acquire
Slide 27: Pillars for Growth in 2023
Pillars for Growth in 2023 Continue Growing Online Sales Expanding Premium Consumer LPT CBD Next Steps Wellness White-Label Segment Sales Toxicity Safety Veterinary Pre-IND Agreement for Meeting Consumer Line Human Pre-IND 4 Meeting 2 3 1 | 27
Slide 28: Thank You!
CSE: INNO | OTC: INNPF | FSE: IP4 Thank You! Iris Bincovich CEO +972.54.301.2842 irisb@InnocanPharma.com InnocanPharma.com | 28
Innocan Pharma — Investor Presentation (February 2023) on 6ix